Yes, the usual practice is to instil one drop into each affected eye once daily, unless a clinician advises otherwise based on individual response.
Persistent conjunctival hyperemia may be managed with lubricating eye drops, but if it lasts more than a week or is accompanied by pain or vision changes, seek an ophthalmology review.
Insert contact lenses only after the drop has been absorbed (approximately 10 minutes) to avoid staining and irritation.
Some OTC lubricants are compatible, but those containing preservatives or anti-inflammatory agents should be spaced at least 5 minutes apart; always confirm with your pharmacist.
Evening dosing reduces the likelihood of daytime redness and aligns with the drug’s peak IOP-lowering effect during nocturnal hours.
A 3 ml bottle provides about 60 drops, which is enough for roughly two months of once-daily use.
Sudden eye pain, severe vision loss, swelling of the eyelid, or signs of inflammation (e.g., yellow discharge) warrant immediate medical attention.
It can exacerbate dryness; using preservative-free artificial tears several hours after the dose can help manage symptoms.
Yes, but keep the bottle in its original packaging, carry a copy of the prescription, and be aware of any country-specific restrictions on ophthalmic medications.
IOP may rise, increasing the risk of glaucoma progression. Contact your eye-care provider promptly to arrange an urgent assessment.
Bimatoprost 0.03% is an eye-care medication that belongs to the prostaglandin-analog class. The active ingredient, bimatoprost, works to lower intra-ocular pressure (IOP) and is supplied in a 3 ml bottle of sterile eye-drop solution. In the United Kingdom the product is prescription-only (Rx) and is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of primary open-angle glaucoma and ocular hypertension.
Bimatoprost mimics the activity of naturally occurring prostaglandins. When a drop is placed in the eye, it:
The drug is absorbed locally; only a tiny fraction reaches systemic circulation, which limits systemic side-effects.
Primary open-angle glaucoma (POAG) - a chronic condition where elevated IOP damages the optic nerve and can lead to irreversible vision loss.
Ocular hypertension - a state of raised IOP without detectable optic-nerve damage, where treatment aims to prevent progression to glaucoma.
Both indications are approved by the MHRA and are supported by NICE guidelines, which recommend prostaglandin analogues as first-line therapy for many patients.
Bimatoprost, when applied to the base of the upper eyelashes, has been shown in clinical studies to increase eyelash length, thickness, and darkness. While this formulation (marketed as Latisse) is FDA-approved in the United States, it is not licensed for this purpose in the UK.
Regulatory disclaimer: Use for eyelash enhancement is off-label and should only be undertaken under the supervision of a qualified ophthalmologist or dermatologist, with a full risk-benefit assessment.
Ideal candidates
Absolute contraindications
Relative contraindications & special populations
If you fall into any of these groups, discuss alternatives with your eye-care provider.
This article provides educational information about Bimatoprost 0.03% and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
